Management
managmant

Eli Kaplan, MD

CEO and Founder
Education:

Medical degree from the University of Bologna, Italy

Professional background:

Dr. Kaplan founded Novaremed in 2008 and has been leading its development in Israel and since 2017 in Switzerland. Prior to founding Novaremed, Dr. Kaplan practiced medicine in Switzerland. He has more than 30 years of experience in the pharmaceutical industry particularly in oncology drug development. He worked at Farmitalia Carlo Erba in Italy (Milan) as a Director of Oncology-Corporate Medical Department, in Germany (Freiburg) as a Medical Director as well as in Israel. In addition, between 1994 and 1998, he founded a consulting firm, Seneb-Pharma, to consult in the field of Research and Development of Drugs and Medical Products. Between 2005 and 2006 he was as a (part time) Medical Director at Oridion BreathID in Israel.

managmant

Sara Mangialaio, MD, PhD

CMO, Head of R&D
Education:

After completing her medical degree at the University of Milan (Italy), Dr. Mangialaio obtained PhD in Immunology at the University of Strasbourg (France) and a Master in Project Management at the George Washington University (USA).

Professional background:

Dr. Mangialaio joined Novaremed in 2017, as Chief Medical Officer and Head of R&D. She has more than 18 years of experience in the pharmaceutical industry. She was previously Therapeutic Area Head, Clinical Program Head and Clinical Science Operation Unit Head at Actelion, where she spent more than 8 years working in multiple indications, including insomnia and psychiatric disorders. Prior to this, she had worked for 9 years at Novartis, where she covered projects spanning from target selection to phase IV. At Novartis and Actelion, she had leadership of clinical, regulatory, diagnostic and biomarker cross-functional global teams and task forces. In addition, she was responsible for successful submissions and interactions with Regulatory Authorities, including drug approval, label negotiation and orphan drug designation. She has long standing experience in people and resource management, as well as in planning and execution of clinical trials.

managmant

Subhasis Roy

Chief Operating Officer
Education:

MBA in Finance from Duke University, NC, USA and Masters’ and Bachelors’ degrees in Commerce from University of Mumbai, India.

Professional background:

Subhasis Roy joined Novaremed in 2018. Previously he was Managing Partner and co-founder of Sirius Healthcare Partners, a healthcare advisory boutique providing advisory and transaction support to emerging healthcare companies. Prior to co-founding Sirius in 2009, he spent over 15 years at bulge bracket Investment Banks (UBS, HSBC, DKB, NatWest) where he acted as strategic advisor and led numerous capital markets, M&A and private placement transactions for listed and emerging companies in healthcare and other sectors in Europe, USA and Asia worth over $11 bn.

managmant

Maurizio Rainisio

Head of Biometry
Education:

Doctorate in Mathematics from Università degli Studi di Milano, Italy.

Professional background:

Maurizio Rainisio has more than 40 years of experience in the pharmaceutical industry, including Ciba Geigy, Roche, Novartis, SFR. In 2000 he joined Actelion Pharmaceuticals as Vice-president, Head of Global Biometry. In 2010 he founded AbaNovus, a company providing consultancy and services in the field of methodology and statistics for clinical studies.

managmant

Liat Hochman

Head of Operations
Education:

M.Sc. degree (cum laude), Microbiology Dep. and B.Sc. degree, Faculty of Life Sciences both from Tel Aviv University, Israel.

Professional background:

Ms. Hochman joined Novaremed in 2011, as Head of Operations. She has over 22 years of recognized management skills and expertise in the clinical research arena. Prior to joining Novaremed, she established and managed the Israeli affiliate of Hesperion – a European CRO headquartered in Basel, Switzerland. At Hesperion Israel, she was being responsible for clinical operations as well as the administration, financial management and human resources. Upon the acquisition of Hesperion by Averion, she was nominated as the Regional Director of Averion Israel.

managmant

Michal Freud-Silverberg, PhD

Head of Clinical Operations
Education:

PhD degree and B.Sc. both, Faculty of Life Sciences, Bar-Ilan University, Israel. M.Sc. degree, Immunology Dep., Weizmann Institute of Science, Israel.

Professional background:

Dr. Silverberg joined Novaremed in 2014. Prior to joining Novaremed, she was a Clinical Project Manager at Averion Israel (previously Hesperion Israel), an international CRO. She has more than 20 years of experience working in the field of clinical research from both CRO and sponsor’s positions and is active in CTrials, the Israeli association of clinical trial professionals.

Board of Directors
managmant

Harry Welten, MBA, Independent Chairman

Over the last 17 years, Mr. Welten was Chief Financial Officer of both public as well as venture capital financed biotech companies. During that time, he has raised more than CHF320 million through IPO, venture capital, M&A as well as debt offerings. He serves on the board of several biotechnology companies in Switzerland and USA. He has an MBA (hons.) from Columbia University, NY, USA.

managmant

Uvi Brand

Mrs. Brand is the Chairperson of the Board of Directors and controlling shareholder of Gefen Biomed Investments Ltd., an Israeli public company. She is also an Investment Advisor at Gefen Investments, an Israeli investment fund investing in Israeli startups with disruptive technologies. Additionally, she manages an occupational clinic in the Israel Electric Corporation. She has a BA in political science.

managmant

Dr. Eli Kaplan

See under Management

managmant

Dr. Isaac Kobrin

Dr. Kobrin is an internist with 15 years of experience in academic medicine both in Israel and the USA. In 1989, Dr. Kobrin joined Hoffmann-La Roche as International Clinical Leader and later on became Global Group Leader of the Cardiovascular Development Group. In 1999, Dr. Kobrin joined Actelion Pharmaceuticals as Senior Vice President, Head of Clinical Development, and member of Actelion’s Executive Committee. In 2009, he became Chief Medical Officer and chairman of the Strategic and Portfolio Board of Actelion. Since 2012, Dr. Kobrin is serving on the Board of Directors of several Swiss biotechnology companies.

managmant

Dr. Perry Molinoff

Dr. Molinoff was formerly Professor and Chairman of Pharmacology at the University of Pennsylvania. He also served as Vice President of Neuroscience Drug Discovery at Bristol Meyers Squibb. He obtained his medical degree from Harvard University in Boston. His background includes more than thirty years of experience in both the academic and industrial sectors. He has served on the board of both publicly traded and private companies.

managmant

Dr. S K Tan

Dr. Tan currently practices in Singapore, having graduated from medical school in 1971. He has postgraduate qualifications in Dermatology and Venereology, and Cosmetic Science, and an MBA from the Maastricht Business School, and is a Fellow of the American Academy of Dermatology (FAAD). He is a founder-partner of the JYSK Group (Singapore) and is an investor and Board member of several biotechnology companies, including Illustris Pharmaceuticals (USA) and Novaremed (Switzerland).

Scientific Advisory Board

Prof. Dan Ziegler

Prof. Dan Ziegler graduated from Heidelberg Medical School, Germany. He holds specializations in Internal Medicine, in Diabetology and in Endocrinology. He is currently Deputy director, Research Group Leader, Professor of Internal Medicine and Consultant Physician at the Institute for Clinical Diabetology, Heinrich Heine University, Düsseldorf, Germany. In addition, Prof. Ziegler is a member of multiple authorized expert panels for clinical guidelines; he has chaired and he is now executive committee member the of Diabetic Neuropathy Study Group of the European Association for the Study of Diabetes (EASD) editorial boards and Prof. Ziegler has published more than 300 original articles, reviews, and book chapters. He is a reviewer and member of editorial boards for many journals, including N Engl J Med, Lancet, Lancet Endocrinol Diabetes, J Am Coll Cardiol, Diabetes, Diabetes Care, Diabetologia, J Clin Endocrinol Metab, Ann Neurol, JAMA Neurol, Pain and Journal of Diabetes Research. He has received multiple awards, including the Camillo Golgi prize of the of the European Association for the Study of Diabetes (EASD). His areas of interest are: pathophysiology, pathology, diagnosis, screening, prevention, and treatment of diabetic polyneuropathy, neuropathic pain, cardiovascular autonomic neuropathy, gastrointestinal motility, and erectile dysfunction; design of clinical trials. He has been principal investigator of numerous clinical trials in diabetic neuropathy for more than 30 years.

Prof. Nadine Attal

Prof. Attal is Associate Professor of therapeutics and pain in University Versailles Saint Quentin (France) and responsible for the Center of Evaluation and Treatment of Pain in Ambroise Paré Hospital (France). Prof. Attal has published 129 peer review papers on pain particularly neuropathic pain since 1988 in high impact factor journals such as Lancet Neurol, Annals Neurol, Neurology, Brain, Pain. Since 2004, she coordinated several European guidelines (EFNS, EAN) on the assessment, pharmacological and neurostimulation treatment of neuropathic pain. Since 2016, she is responsible for the panel Pain of the European Academy of Neurology. She was at the Editorial board of the Journal Pain from 2004 to 2008, field editor of the Journal E J Pain and section editor of the Journal Pain Reports (France), member of the IASP Council since June 2018 and of the French Society of Pain Council since 2016. She is also Chair of the pain panel of the European Academy of Neurology.

Prof. Elon Eisenberg

Prof. Elon Eisenberg graduated from Sackler School of Medicine, Tel-Aviv University in Israel. He completed a residency in Neurology, at Rambam Medical Center, Haifa, Israel, and Neurology – Pain Fellowship at Massachusetts General Hospital, Harvard Medical School in Boston, USA. Prof. Eisenberg has been the director of the Institute of Pain Medicine at Rambam Health Care Campus, Haifa, Israel, and the President of the Israeli Pain Association. He is currently the director of the Pain Research Unit at the Institute of Pain Medicine, Rambam Health Care Campus. He is a Professor of Neurology and Pain Medicine at the Faculty of Medicine and holds the Otto Barth Family Academic Chair in Biomedical Science at the Technion – Israel Institute of Technology. His main areas of research include mechanisms and treatment of pain with special emphasis on neuropathic pain, CRPS, cancer pain, opioids and cannabinoids. Prof. Eisenberg has published about two-hundred articles, book chapters and abstracts in various areas of pain.

Prof. Robert H. Dworkin

Dr. Dworkin received his BA from the University of Pennsylvania and his PhD from Harvard University. He is Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry, Professor in the Center for Health + Technology, and Director of the Anesthesiology Clinical Research Center at the University of Rochester School of Medicine and Dentistry. He is Director of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION), a public-private partnership with the US Food and Drug Administration (FDA) and a Special Government Employee of the FDA Center for Drug Evaluation and Research. He previously served as a consultant to and member of the FDA Anesthetic and Life Support Drugs Advisory Committee and as a member of the US Centers for Disease Control and Prevention Herpes Zoster Working Group. He is an Associate Editor of Pain, and a member of the Editorial Boards of Journal of Pain, Canadian Journal of Pain, and Current Pain and Headache Reports. He received the American Pain Society’s Wilbert E. Fordyce Clinical Investigator Award in 2005 and John and Emma Bonica Public Service Award in 2014, the Eastern Pain Association’s John J. Bonica Award in 2011 and Raymond Houde Lectureship Award in 2018, the American Academy of Neurology’s Mitchell B. Max Award for Neuropathic Pain in 2015, and the American Academy of Pain Medicine’s Founders Award in 2018. His major research interests are (1) methodologic aspects of analgesic clinical trials and (2) treatment and prevention of chronic and acute neuropathic and musculoskeletal pain. The primary focus of his current research involves the identification of factors that increase the assay sensitivity of clinical trials to detect differences between an active and a control or comparison treatment.

Dr. Doriano Fabbro, PhD

Dr. Fabbro has a PhD in Biology and has 25 years of experience in drug discovery in Pharma (Ciba-Geigy, Novartis) as well as Biotech (Piqur Therapeutics), following 10 years in academia. Until 2005, he was Executive Director for the Oncology Drug Discovery effort at the Novartis Institute for Biomedical Research (NIBR) and member of the NIBR Oncology Advisory Board overseeing significant part of NIBR’s global Oncology Drug Discovery portfolio from target discovery to clinical development. From 2005 to 2012, he was Executive Director of the NIBR Expertise Platform Kinases dedicated to global Kinase Drug Discovery projects in Oncology, Immunology, Inflammation, Respiratory Disease, Muscular Disease and Cardiovascular indications. Since 2012 he is Chief Scientific Officer of Piqur Therapeutics (Basel Switzerland), a small biotech company devoted to the discovery of PI3K/mTOR inhibitors as well as scientific advisor for several pharmaceutical companies in the area of kinase drug discovery. During his career, he contributed to the development of the following approved oncology drugs such as Glivec® (Imatinib, BcrABL inhibitor), Tasigna® (Nilotinib, BcrAbl inhibitor), Afinitor® (Everolimus, mTOR inhibitor) and Ryadpt® (Midostaurin, Kit and Flt-3 inhibitor).